A caregiver's guide to ZOLGENSMA® (onasemnogene abeparvovec) treatment

Your child's doctor has given you this guide because your child has been prescribed Zolgensma®.
This guide aims to provide practical information to support discussions with your doctor.

If your child experiences any side effects, talk to your child's doctor, nurse or pharmacist/other healthcare professional. This includes any possible side effects not listed in this guide.

If you have any questions or concerns about Zolgensma, speak with your child's doctor, nurse or pharmacist/other healthcare professional.

NOVARTIS

SG2305157984 | Date of preparation: April 2023

Dear parent, carer or family member,

Thank you for taking the time to read this guide. You have been given this guide as your child has been diagnosed with spinal muscular atrophy (SMA and has been prescribed Zolgensma by the doctor.

You may need to refer to this information again, so please keep a copy of this guide.

This guide has been developed to provide useful information on:

- **Zolgensma and how it works**
- **Important safety information and possible side effects of Zolgensma**
- **Each step of the Zolgensma treatment journey**

If you have any questions or concerns about this medicine or your child's health and wellbeing, please speak with your child's doctor, nurse or pharmacist/other healthcare professional.

Useful contacts

SMA, spinal muscular atrophy.

What is in this guide?

SMA, spinal muscular atrophy.

SG2305157984 | Date of preparation: April 2023

What is SMA?

Spinal muscular atrophy (SMA) is a rare, serious, inherited condition. SMA occurs when there is a missing or abnormal version of a gene needed to make an essential protein called 'survival motor neuron' (SMN). Lack of SMN protein causes nerves that control muscles (motor neurons) to die. This results in muscles becoming weak and wasting away, with eventual loss of movement and difficulty with functions such as breathing, swallowing, feeding and speaking.

Although lower motor neurons are affected by SMA, the ability to think, learn, and build relationships is unchanged.

Healthy people



Brain

In healthy people, signals for muscle movement are generated.

Motor neurons

These special nerves carry signals from the brain to the muscles to control movement. There are two types of motor neurons: upper motor neurons that carry signals from the brain to the brain stem and spinal cord, and lower motor neurons that carry signals from the upper motor neurons to the muscles.

Muscles

Muscles tighten or relax in response to signals carried by the motor neurons. This causes the body to move, and is essential for functions such as breathing, swallowing, feeding and speaking.

People affected by SMA



Brain

In people with SMA, signals for muscle movement are generated.

Dysfunctional motor neurons

People with SMA have a genetic mutation that causes their lower motor neurons to deteriorate and stop working. This means that signals in the brain are not carried from the spinal cord to the muscle.

Weakened/wasted muscles

If the muscles no longer receive signals telling them to move they can waste away (atrophy) and become increasingly weaker. This leads to difficulty with movement, breathing, swallowing, feeding and speaking.

SMA, spinal muscular atrophy; SMN, survival motor neuron.

SMA, spinal muscular atrophy.

What causes SMA?

Healthy people

Survival motor neuron (SMN) protein

For motor neurons to be able to work properly and survive, the body needs, among other things, a protein called SMN or 'survival motor neuron'. Without SMN protein, motor neurons stop working and die, and muscles become weaker with eventual loss of movement and difficulty with functions such as breathing, swallowing, feeding and speaking.

Survival motor neuron *(SMN)* genes

In healthy people, the body is able to produce the SMN protein from genes called *SMN* genes. There are two types of ***SMN* gene, *SMN1* and *SMN2*:**

Functional SMN protein

Survival motor neuron 1 *(SMN1)*

The *SMN1* gene is the primary gene and produces most of the SMN protein that motor neurons need to work properly.



Insufficient amounts of functional SMN protein

Survival motor neuron 2 *(SMN2)*

Although the *SMN2* gene also produces SMN protein, it makes several versions of this protein and only small amounts of these work properly ('functional SMN protein'). The *SMN2* gene therefore acts like a 'back-up' to support SMN protein production, but is not able to produce sufficient SMN protein on its own.

- Functional SMN protein
- Non-functional SMN protein

SMA, spinal muscular atrophy; SMN, survival motor neuron.

People affected by SMA

In people with SMA, the *SMN1* gene is either faulty (mutated) or completely missing

The *SMN2* gene cannot produce enough functional SMN protein to make up for the loss of the *SMN1* gene. As a result, in SMA there is not enough functional SMN protein produced to keep motor neurons healthy and working properly.



SMA, spinal muscular atrophy; SMN, survival motor neuron.

SG2305157984 | Date of preparation: April 2023

Who gets SMA?

As SMA is caused by a faulty (mutated or missing gene, it is considered a genetic disease and is usually inherited).

A child inherits two copies of each gene, one from their mother and one from their father. For a child to be born with SMA, they must inherit a faulty gene from both their mother and their father. If either copy of the gene (from the mother or from the father) is faulty, the other parent's unaffected gene can make sure enough SMN protein is produced for the motor neurons to work properly. People who have one unaffected copy of the *SMN1* gene and one faulty copy are known as 'carriers' and typically do not show any symptoms. Most carriers have no idea they carry the faulty gene until they have a child born with SMA.

Around **1 in 50** people are carriers of SMA, although this will vary slightly depending on your geographical location.



The chance of two carrier parents having a child with SMA is **25%** in each pregnancy.

SMA is a rare disease, affecting around **1 in 10,000** newborns, and can impact any race or sex.

SMA, spinal muscular atrophy; SMN, survival motor neuron.

How is SMA inherited?

SMA typically happens if a child inherits two copies of the faulty or missing *SMN1* gene, one from their mother and one from their father. This type of inheritance pattern is referred to as 'recessive', and means that, generally, both parents must be healthy carriers for a 25% chance the disease will be inherited.



Healthy | Healthy Carrier | Affected by SMA

All future pregnancies will carry the same 25% chance of having a child affected by SMA, so it is important to discuss your options with your medical team when making decisions on expanding your family.

SMA, spinal muscular atrophy; SMN, survival motor neuron.

SG2305157984 | Date of preparation: April 2023

Severity and symptoms of SMA

You may hear your child's medical team refer to 'motor milestones', which are functional abilities which help to assess SMA and its progression. Motor milestones relevant for children with SMA include their ability to:


Raise their head


Grasp something in their hand


Crawl


Sit


Roll over


Stand and walk

These milestones, together with the age at which symptoms start, are used to help determine the severity of SMA.

The earlier symptoms of SMA present, the more severe the disease is likely to be. In this way, the childhood forms of SMA can be deceptive and difficult to diagnose, as children can appear unaffected at birth or even later into childhood.

Often in SMA, symptoms present within the first 6 months of life, but in some cases, symptoms may occur before birth, with mothers noticing that their child's movements slow down in the last weeks of pregnancy

For other children, symptoms may not be apparent until much later on in childhood or adolescence. Occasionally symptoms don't appear until adulthood

Without intervention or treatment, children with more severe forms of SMA have a shortened lifespan. With early medical intervention and treatment, deterioration can be slowed, with children often able to achieve milestones rarely seen during the natural course of the disease.

SMA, spinal muscular atrophy.

SMA is a disease with a range of symptoms that may vary in severity

Age at onset of symptoms: Birth, ≤6 months, 18 months, 18 years

Types of SMA	Symptoms
Decreased fetal movement (SMA Type 0)	In the most severe form of SMA, symptoms usually begin to develop before birth. The child's movements may slow down during pregnancy.
Unable to sit independently (SMA Type 1)	**Symptoms typically develop by age 6 months and include:** • Poor head control • Weak legs and arms • Difficulty breathing and swallowing • Weak cough and cry
Able to sit and may stand, unable to walk independently (SMA Type 2)	**Symptoms typically appear between 6–18 months of age and include:** • Weak legs and arms • Struggles to sit unsupported • Slow/lost motor milestones • Swallowing and coughing difficulties • Tremor • Pain and difficulty in moving joints • Twisting or curving of the spine • Difficulty breathing in some cases
Independent walking (SMA Type 3)	Symptoms usually develop from early childhood (>18 months) to late adolescence. People with this form of SMA may have poor balance, and have problems with standing up and walking/climbing stairs.
Independent walking into adulthood (SMA Type 4)	In the mildest form of SMA, symptoms don't appear until adulthood. People with this form of SMA typically have mild weakness, without breathing difficulties.

SMA, spinal muscular atrophy.

SG2305157984 | Date of preparation: April 2023

About Zolgensma

Zolgensma is used to treat babies and young children less than 2 years of age who have the rare, serious, inherited condition 'spinal muscular atrophy' (SMA).

What is Zolgensma?

Zolgensma is a type of medicine called a 'gene therapy'. It contains the active ingredient onasemnogene abeparvovec which contains human genetic material.

How does Zolgensma work?

Zolgensma does not change your child's DNA, but replaces the function of the faulty or missing *SMN* gene. Zolgensma works by supplying a fully functioning copy of the *SMN* gene which then helps the body produce enough SMN protein. The copy of the *SMN* gene is taken to the cells where it is needed by a gene delivery vehicle known as a 'vector'.

The vector that delivers the *SMN* gene is made from a modified virus called adeno-associated virus 9, or AAV9. This type of modified virus does not cause disease in humans. To make the vector, most of the DNA of the virus is removed and the new *SMN* gene is put inside.

AAV, adeno-associated virus; DNA, deoxyribonucleic acid; SMA, spinal muscular atrophy; SMN, survival motor neuron.



Zolgensma in advanced SMA

Zolgensma can rescue motor neurons that are still alive and capable of growth, but not dead motor neurons. Children with less severe symptoms of SMA may have enough live motor neurons to benefit from Zolgensma treatment. Zolgensma may not work as well in children with severe symptoms.

AAV, adeno-associated virus; DNA, deoxyribonucleic acid; SMA, spinal muscular atrophy; SMN, survival motor neuron.

SG2305157984 | Date of preparation: April 2023

Understanding the risks of Zolgensma

Like all medicines, Zolgensma can have side effects, although not everybody gets them.

IF YOUR CHILD EXPERIENCES ANY SIDE EFFECTS, TALK TO YOUR CHILD'S DOCTOR, NURSE OR PHARMACIST/OTHER HEALTHCARE PROFESSIONAL IMMEDIATELY.

Important safety information and when to seek medical attention

Liver problems

Tell your child's medical team before your child is given this medicine if your child has, or has had any liver problems. In some cases, Zolgensma can cause an immune response that could lead to an increase in enzymes (proteins found within the body) produced by the liver or injury to the liver.

Injury to the liver can lead to serious outcomes, including liver failure and death. Possible signs you need to look out for after your child is given this medicine include vomiting, jaundice (yellowing of the skin or of the whites of the eyes), or reduced alertness. Tell your child's doctor straight away if you notice your child develops any symptoms suggestive of injury to the liver.

Abnormal blood clotting

Zolgensma may increase the risk of abnormal clotting of blood in small blood vessels (thrombotic microangiopathy), generally within the first 2 weeks after Zolgensma treatment. These blood clots could affect your child's kidneys. Tell your doctor immediately if you notice signs and symptoms such as bruising easily, seizures (fits) or decrease in urine output.
Extremely close attention should be paid to these signs and symptoms, as abnormal blood clotting (thrombotic microangiopathy) is serious and can be life-threatening if it is not treated.

Low platelet count

Zolgensma can lower blood-platelet counts (thrombocytopenia), generally within the first 2 weeks following Zolgensma treatment. Possible signs of a low blood-platelet count you need to look out for after your child is given Zolgensma include abnormal bruising or bleeding.

Speak to your doctor if you see signs such as bruising or bleeding for longer than usual if your child has been hurt.

Troponin-I

Zolgensma can raise levels of a heart protein called troponin-I that may indicate injury to the heart. You need to look out for possible signs of heart problems after your child is given Zolgensma, such as pale grey or blue skin colour, difficulty in breathing (e.g. rapid breathing, shortness of breath), swelling of the arms and legs or of the belly.

Your child will have blood tests to check liver function, kidney function, the amount of blood cells (including red blood cells and platelets) and troponin-I level before treatment with Zolgensma.

For at least 3 months following treatment, your child will have regular blood tests to check liver function and to monitor for changes in platelets and troponin-I levels. Depending on the values and other signs and symptoms, further evaluations may be required. The duration of testing will be decided by your child's doctor.

Do not hesitate to talk to your child's medical team if you have any questions on Zolgensma.

SG2305157984 | Date of preparation: April 2023

Understanding the risks of Zolgensma
(continued)

Like all medicines, Zolgensma can have side effects, although not everybody gets them.

IF YOUR CHILD EXPERIENCES ANY SIDE EFFECTS, TALK TO YOUR CHILD'S DOCTOR, NURSE OR PHARMACIST/OTHER HEALTHCARE PROFESSIONAL IMMEDIATELY.

Allergies

Your child must not be given Zolgensma if they are allergic to any of the ingredients (including onasemnogene abeparvovec, tromethamine, magnesium chloride, sodium chloride, poloxamer 188 and hydrochloric acid).

Other medicines and Zolgensma

Zolgensma will be given to your child once only. Tell your child's doctor or nurse if your child is taking, has recently taken or might take any other medicines.

Corticosteroids

Your child will also be given corticosteroids (prednisolone or equivalent) for a period of time before and after treatment with Zolgensma. The length of time that corticosteroids will be given to your child following Zolgensma treatment will vary depending on liver enzyme values and other signs and symptoms, and will be decided by your child's doctor. This period will be a minimum of 2 months, and can be up to 1 year or longer.

Corticosteroids will help manage any potential increase in liver enzymes that your child could develop following an immune response to Zolgensma. The dose of corticosteroid your child will receive will be worked out by your child's doctor depending on your child's weight.

During corticosteroid dosing, your child may face new infections or other usual child illnesses which may require the use of other medicines. Prior to treatment with any other medicines, or if you have any questions about corticosteroids, it is important to consult your child's doctor, nurse or pharmacist/ other healthcare professional.

Infection

Your child may have a weakened immune system due to corticosteroids, meaning that infections that healthy people can usually fight off may make your child seriously ill. If your child develops an infection (e.g. cold, flu or bronchiolitis) **before** or **after** being treated with Zolgensma this could possibly lead to other more serious complications that may require urgent medical attention.

You should tell your child's doctor straight away if you notice your child develops any signs and symptoms suggestive of infection **before** or **after** Zolgensma treatment, such as:

- Coughing
- Wheezing
- Sneezing
- Runny nose
- Sore throat
- Fever

It is important to prevent infections before and after treatment with Zolgensma by avoiding situations that may increase the risk of your child getting infections. You and any other close contacts with your child can help to prevent infection by following good hand hygiene, good coughing/sneezing etiquette, and limiting potential contacts.

SG2305157984 | Date of preparation: April 2023

Understanding the risks of Zolgensma
(continued)

Vaccinations

As corticosteroids can affect the body's immune system, your child's doctor may decide to delay giving some vaccinations to your child while they are receiving corticosteroid treatment. Talk to your child's doctor, nurse or pharmacist/other healthcare professional if you have any questions.

IN SUMMARY, SEEK URGENT MEDICAL ATTENTION IF YOUR CHILD DEVELOPS ANY OF THE FOLLOWING SIGNS OR SYMPTOMS:

- **Bruising** or **bleeding** for longer than usual if your child has been hurt – these may be signs of a low blood-platelet count (thrombocytopenia).
- **Bruising easily**, **seizures** (fits) or **decrease in urine output** – these may be signs of abnormal clotting of blood in small blood vessels (thrombotic microangiopathy). Extremely close attention should be paid to these signs and symptoms, as abnormal blood clotting can be life-threatening if it is not treated.
- **Vomiting**, **jaundice** (yellowing of the skin or of the whites of the eyes), or **reduced alertness** – these may be signs of possible problems with the liver (including liver failure).
- **Pale grey or blue skin color**, **difficulty in breathing** (e.g. rapid breathing, shortness of breath), **swelling of the arms and legs or of the belly - these may be signs of possible problems with the heart.**
- **Coughing**, **wheezing**, **sneezing**, **runny nose**, **sore throat**, or **fever** – these may be signs of infection (e.g. cold, flu or bronchiolitis).

Treatment with Zolgensma

The steps on the following pages will help you and your family understand what to expect next.

1. **Before treatment**
2. **Treatment day**
3. **After treatment**

SG2305157984 | Date of preparation: April 2023

1. Before treatment

To help decide if Zolgensma is suitable for your child, your child's doctor will carry out tests for antibodies before treatment.

AAV9 antibody test

Antibodies are produced by the body's immune system to help protect it against disease. The presence of certain antibodies, called AAV9 antibodies, can cause your child to have an immune response to Zolgensma. To help decide if Zolgensma is suitable for your child, your child's doctor will carry out tests for antibodies before treatment.

Your child may have elevations in AAV9 antibodies. If the baby is new-born, it may be antibodies that have been transferred from the mother to the baby during pregnancy, and these elevations will often decrease over time after birth. If your child has elevations in AAV9 antibodies after their first test, they will be eligible for retesting after a period of time. If you have any questions, please ask your child's doctor.

Blood tests

Before Zolgensma treatment your child will have blood tests to check and establish baseline levels for:

- Liver function
- Kidney function
- The amount of blood cells (including red blood cells and platelets)
- Troponin-I level

These measurements will help your doctor to monitor your child's levels after Zolgensma treatment.

AAV, adeno-associated virus.

Corticosteroids

24 hours before being treated with Zolgensma, your child will be given corticosteroids (prednisolone or equivalent) to manage potential increases in liver enzymes.

The dose of corticosteroid your child will receive will be worked out by your child's doctor depending on the child's weight. To make sure that your child does not miss corticosteroid dosing, tell your child's doctor, nurse or pharmacist/other healthcare professional in the event of vomiting before treatment with Zolgensma.

Infection

It is important to let your child's doctor, nurse or pharmacist/other healthcare professional know straight away if your child develops symptoms of infection **before** or **after** Zolgensma. If your child develops any signs or symptoms suggestive of infection before treatment with Zolgensma, the infusion may need to be delayed until the infection is resolved. If your child develops symptoms after treatment with Zolgensma it may lead to medical complications that may require urgent medical attention.
See page 17 for signs of a possible infection.

Overall health

Before being treated with Zolgensma, it is important that your child's overall health is adequate, otherwise treatment may need to be postponed. This includes being hydrated, having good nutrition and being free of any active infections. If you have any concerns about your child's overall health before treatment with Zolgensma, please speak to your child's doctor, nurse or pharmacist/other healthcare professional.

SG2305157984 | Date of preparation: April 2023

2. Treatment day

Your child's medical team will ensure you know exactly what to expect on the day of treatment and how to prepare.

Prednisolone

The first dose of corticosteroids (prednisolone or equivalent) will have been given to your child 24 hours before being treated with Zolgensma. See page 21 for information on corticosteroid dosing before treatment with Zolgensma.

On the day of treatment your child will receive their second dose of oral corticosteroids (prednisolone or equivalent) as prescribed. The corticosteroid dosing regimen is important in managing any potential increases in liver enzymes. To make sure that your child does not miss corticosteroid dosing, tell your child's doctor, nurse or pharmacist/other healthcare professional in the event of vomiting after corticosteroid dosing.

Zolgensma will be given to your child ONCE only.

Zolgensma infusion

Zolgensma will be given to your child by a single, intravenous infusion. This involves placing a catheter (plastic tube) into one of your child's veins using a needle. A secondary, back-up catheter will also be inserted in case of any blockage in the primary catheter. The infusion will be given by a doctor or nurse trained in the management of SMA. The infusion will take around 60 minutes.

The amount of Zolgensma your child will receive will be worked out by your child's doctor depending on the child's weight.

SMA, spinal muscular atrophy.

SG2305157984 | Date of preparation: April 2023

3. After treatment

The duration of hospitalization after treatment with Zolgensma will be decided by your child's doctor. If you have any questions, talk to your child's medical team.

Possible side effects

Like all medicines, this medicine can have side effects, although not everybody gets them.

SEEK URGENT MEDICAL ATTENTION IF YOUR CHILD DEVELOPS ANY OF THE FOLLOWING SERIOUS SIDE EFFECTS.

- **Bruising** or **bleeding** for longer than usual if your child has been hurt – these may be signs of a low blood-platelet count (thrombocytopenia).
- **Bruising easily, seizures** (fits) or **decrease in urine output** – these may be signs of abnormal clotting of blood in small blood vessels (thrombotic microangiopathy). Extremely close attention should be paid to these signs and symptoms, as abnormal blood clotting can be life-threatening if it is not treated.
- **Vomiting, jaundice** (yellowing of the skin or of the whites of the eyes), or **reduced alertness** – these may be signs of possible problems with the liver (including liver failure).
- **Pale grey or blue skin color, difficulty in breathing** (e.g. rapid breathing, shortness of breath), **swelling of the arms and legs or of the belly – these may be signs of possible problems with the heart.**
- **Coughing, wheezing, sneezing, runny nose, sore throat,** or **fever** – these may be signs of infection (e.g. cold, flu or bronchiolitis).

Talk to your child's medical team straight away if your child develops any other side effects. These can include:

Common (may affect up to 1 in 10 people)

- Vomiting
- Fever

Reporting of side effects:

If your child experiences any side effects or you are concerned that something might be wrong , talk to your child's doctor, nurse or pharmacist/ other healthcare professional immediately.

This includes any possible side effects mentioned or not mentioned in this guide.

Regular follow-ups

Following Zolgensma treatment, your child will continue to be under regular supervision of a dedicated healthcare team. Your child will require follow-up visits as necessary, whether these are for general check-ups, if your child is experiencing any side effects, or if you have any concerns or queries.

Appropriate standard of care for patients with SMA, including supportive care, is necessary and will be provided. It is important to discuss with your child's doctor how the healthcare team will continue to support your child.

SG2305157984 | Date of preparation: April 2023

3. After treatment

Corticosteroids dosing after Zolgensma

Your child will be given corticosteroid treatment daily for around 2 months after being given Zolgensma. This period may be prolonged if your child's liver enzymes do not decrease quickly enough, until they decrease to an acceptable level. The dose of corticosteroid given to your child will be slowly reduced during this time until treatment can be fully stopped.

Your child's medical team will decide and explain when and how they will stop this treatment for your child. To make sure that your child does not miss corticosteroid dosing, tell your child's doctor, nurse or pharmacist/other healthcare professional in the event of vomiting or any missed doses **(for any reason)** after treatment with Zolgensma. It is important to keep to the prescribed dosing of corticosteroids.

Do not stop corticosteroid treatment prior to discussion with your child's doctor, nurse, or pharmacist/other healthcare professional.

If you have any questions about corticosteroids, talk to your child's doctor, nurse or pharmacist/other healthcare professional.

Regular blood tests

Following Zolgensma treatment your child will have regular blood tests for:

- Liver function – these tests will take place for at least 3 months after treatment to monitor for increases in liver enzymes. If your child's liver function worsens after Zolgensma treatment, or they show any signs of illness, they will be promptly assessed and closely monitored by their doctor.
- Blood-platelet count and troponin-I – these will take place for a period of time after treatment to monitor changes in platelets and troponin-I levels.

It is important to keep to the scheduled blood tests.

Depending on the results of these blood tests, as well as other signs and symptoms, further testing may be required. It is important to closely follow the blood test schedule and to immediately report to your child's medical team all signs and symptoms that your child may develop after they receive their treatment.

Management of your child's bodily waste

Some of the active substance in Zolgensma may be excreted through your child's bodily waste after treatment. You and other people who care for your child should follow good hand-hygiene as outlined below for **at least 1 month** after your child's treatment with Zolgensma.

Wear protective gloves when coming into direct contact with your child's bodily fluids (urine) or waste (faeces).

Wash hands thoroughly afterwards with soap and warm running water, or an alcohol-based hand sanitizer.

Use double plastic bags to dispose of soiled nappies and other waste. Disposable nappies may still be disposed of in household waste.

If you have questions on how to handle your child's bodily waste, please talk to your child's doctor, nurse or pharmacist/other healthcare professional.

SG2305157984 | Date of preparation: April 2023

3. After treatment

Supportive care

While Zolgensma supplies a fully functioning copy of the *SMN* gene, your child still has SMA.

Additional supportive therapies used to care for people with SMA include:

Orthopedic treatments

Physiotherapy

Support with nutrition, eating and drinking

Breathing support, for example with a sleep mask

Prevention of airway infections (e.g. prevention of flu and pneumonia with vaccinations)

Removal of secretions from the airways

Your child's healthcare team will work with you to ensure your child's supportive care needs are managed.

SMA, spinal muscular atrophy; SMN, survival motor neuron.

When to seek medical attention

Seek urgent medical attention in any of the following circumstances:

In some cases, Zolgensma can affect the function of the liver and lead to injury of the liver. Possible signs you need to look out for after your child is given this medicine include **vomiting**, **jaundice** (yellowing of the skin or of the whites of the eyes), or **reduced alertness.**

Zolgensma can lower blood-platelet count (thrombocytopenia). Speak to your doctor if you see signs such as **bruising** or **bleeding** for longer than usual if your child has been hurt.

Zolgensma can increase the risk of abnormal clotting of blood in small blood vessels (thrombotic microangiopathy). Tell your doctor immediately if you see signs and symptoms such as **bruising easily**, **seizures** (fits) or **decrease in urine output.**

Zolgensma may cause raised levels of a heart/cardiac-specific protein called 'troponin-I' that may indicate injury to the heart. Speak to your doctor immediately if you see signs and symptoms such as **pale grey or blue skin color, difficulty in breathing** (e.g. rapid breathing, shortness of breath) or **swelling of the arms and legs or of the belly.**

Tell your doctor in the event of **vomiting before or after treatment** with Zolgensma, to make sure that your child does not miss corticosteroid (prednisolone or equivalent) dosing.

Tell your doctor immediately if your child develops any signs and symptoms suggestive of infection (e.g. cold, flu or bronchiolitis) **before** or **after** being treated with Zolgensma, as this could possibly lead to other more serious complications that may require urgent medical attention. Signs to look out for are **coughing**, **wheezing**, **sneezing**, **runny nose**, **sore throat**, or **fever.**

SG2305157984 | Date of preparation: April 2023

Institution/ clinic contact details

Your child will continue to be monitored following Zolgensma infusion by a team of healthcare professionals. If you have any concerns and want to speak to your child's doctor or healthcare team, you can use the below form to note down the contact details of the institution/clinic.

Name:
Role:
Contact number:
Contact e-mail:

Name:
Role:
Contact number:
Contact e-mail:

Name:
Role:
Contact number:
Contact e-mail:

Name:
Role:
Contact number:
Contact e-mail:

Name:
Role:
Contact number:
Contact e-mail:

Name:
Role:
Contact number:
Contact e-mail:

Name:
Role:
Contact number:
Contact e-mail:

Name:
Role:
Contact number:
Contact e-mail:

Name:
Role:
Contact number:
Contact e-mail:

Name:
Role:
Contact number:
Contact e-mail:

Name:
Role:
Contact number:
Contact e-mail:

Name:
Role:
Contact number:
Contact e-mail:

SMA, spinal muscular atrophy.

Common words to know

Adeno-associated virus 9 (AAV9)
Adeno-associated virus 9 (AAV9) is a type of virus. AAV9 can be modified so that it does not cause disease in humans. In Zolgensma, modified AAV9 is the vector used to deliver the fully functioning copy of the SMN gene.

Antibodies
Antibodies are produced by the body's immune system to help protect it against disease. Each type of antibody is unique and defends the body against a specific type of disease.

Atrophy
Atrophy means to waste away or shrink. For example, a muscle that is wasting away is called an atrophied muscle.

Brain stem
The brain stem is a part of the brain that supports critical functions in the body including breathing and sleep. The brain stem joins the spinal cord with the rest. of the brain.

Corticosteroids
Corticosteroids are a type of medicine which suppress the immune system in order to try to help manage any potential increase in liver enzymes after treatment with Zolgensma.

Deoxyribonucleic acid (DNA)
DNA (deoxyribonucleic acid) is the hereditary material in humans and almost all other organisms. Nearly every cell in a person's body has the same DNA.

Genes
Sets of instructions that can tell the body how to make proteins. Genes come in pairs; one copy inherited from each parent.

Gene therapy
Gene therapy is a way of treating or preventing progression of a disease using genes. There are different types of gene therapy that work in different ways. These include replacing or repairing missing or faulty genes; adding a new gene to help another medicine work better; or stopping the instructions from a gene that is producing too much of a protein that then becomes toxic to the body.

Genetic disease
A medical condition caused by a faulty or missing gene or genes.
Genetic diseases are inherited. SMA is an example of a genetic disease.

Intravenous infusion
An infusion into a vein using a catheter (plastic tube), which is inserted into the vein using a needle.

Motor neuron
These special nerves carry signals from the brain to the muscles to control movement.

There are two types of motor neurons: upper motor neurons that carry signals from the brain to the brain stem and spinal cord, and lower motor neurons that carry signals from the upper motor neurons to the muscles.

Platelets
A type of cell that is found in the blood, which is responsible for blood clotting.

Prednisolone
Prednisolone is a type of medicine called a corticosteroid, which helps to manage any potential increase in liver enzymes after treatment with Zolgensma.

Proteins
Proteins are important molecules involved in nearly every function in the body. Proteins help build the cells of the body, while also helping cells transport and produce important substances, repair and survive.

Side effect
A side effect is a secondary, and usually undesirable, effect of a medicine.

Spinal muscular atrophy (SMA)
SMA is a rare disease that causes muscles to gradually become weaker because specialized nerve cells in the body that control muscle movement, called motor neurons, stop working. The motor neurons deteriorate and stop working because they do not have enough SMN protein.

SMN1 gene
The *SMN1* gene is the primary *SMN* gene, producing the SMN protein the motor neurons need to work properly. In people with SMA, both copies of this gene are faulty or missing. This means that the cells of the body are not able to produce enough SMN protein.

SMN2 gene
The *SMN2* gene acts as a 'back-up' to support SMN protein production. *SMN2* only produces small amounts of functional SMN protein.

Survival motor neuron (SMN) protein
SMN protein is vital for motor neurons to work properly and survive. Without enough SMN protein motor neurons deteriorate and stop working. SMN protein is produced by the body from the *SMN* gene.

SG2305157984 | Date of preparation: April 2023

Notes

This guide has been produced by Novartis Europharm Limited. The information provided is for educational purposes only and is not intended to replace discussions with your doctor or care team. Information is related to spinal muscular atrophy and is meant as a general overview.

NOVARTIS

zolgensma® (onasemnogene abeparvovec)

Novartis (Singapore) Pte Ltd
20 Pasir Panjang Road, #10-25/28, Mapletree Buisness City,
Singapore 117439
Phone: +65 6722 6010 I Fax: +65 6323 4335
www.novartis.com.sg

EU RMP v2.2
This document has been approved by HSA
on 21-04-2023
Date: APR-2023 I SG2305157984